Transcriptional regulation of drug-resistance genes in Candida albicans biofilms in response to antifungals

Journal of Medical Microbiology

Volumn 60, Issue 9, 2011, Pages 1241-1247

  Watamoto, T ^a,b   Samaranayake, L P ^a   Egusa, H ^b   Yatani, H ^b   Seneviratne, C J ^a  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

^b OSAKA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; CASPOFUNGIN; CDR1 PROTEIN; CDR2 PROTEIN; ERG11 PROTEIN; FKS1 PROTEIN; FUNGAL PROTEIN; FUNGAL RNA; KETOCONAZOLE; MULTIDRUG RESISTANCE PROTEIN 1; PIL1 PROTEIN; UNCLASSIFIED DRUG;

ANTIFUNGAL RESISTANCE; ANTIFUNGAL SUSCEPTIBILITY; ARTICLE; BIOFILM; CANDIDA ALBICANS; CELL ADHESION; CONTROLLED STUDY; DRUG RESPONSE; FUNGUS CULTURE; FUNGUS GROWTH; GENETIC ASSOCIATION; NONHUMAN; PLANKTONIC FORAMINIFERA; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; TRANSCRIPTION REGULATION; UPREGULATION;

EID: 80051718125     PISSN: 00222615     EISSN: None     Source Type: Journal    
DOI: 10.1099/jmm.0.030692-0     Document Type: Article

References (42)

1. Baillie, G. S. & Douglas, L. J. (1999). Candida biofilms and their susceptibility to antifungal agents. Methods Enzymol 310, 644-656.
2. Beck-Sagué, C. M., Jarvis, W. R. & National Nosocomial Infections Surveillance System (1993). Secular trends in the epidemiology of nosocomial fungal infections in the United States, 1980-1990. J Infect Dis 167, 1247-1251.
3. Beggs, W. H. (1989). Development of phenotypic resistance to direct lethal miconazole action by Candida albicans entering stationary phase. Mycopathologia 108, 201-206.
4. Brajtburg, J., Powderly, W. G., Kobayashi, G. S. & Medoff, G. (1990). Amphotericin B: current understanding of mechanisms of action. Antimicrob Agents Chemother 34, 183-188.
5. Chandra, J., Mukherjee, P. K., Leidich, S. D., Faddoul, F. F., Hoyer, L. L., Douglas, L. J. & Ghannoum, M. A. (2001). Antifungal resistance of candidal biofilms formed on denture acrylic in vitro. J Dent Res 80, 903-908.
6. Edlind, T. D. & Katiyar, S. K. (2004). The echinocandin ''target'' identified by cross-linking is a homolog of Pil1 and Lsp1, sphingolipid-dependent regulators of cell wall integrity signaling. Antimicrob Agents Chemother 48, 4491.
7. Ellepola, A. N. & Samaranayake, L. P. (2001). Adjunctive use of chlorhexidine in oral candidoses: a review. Oral Dis 7, 11-17.
8. Ellis, D. (2002). Amphotericin B: spectrum and resistance. J Antimicrob Chemother 49 (Suppl. 1), 7-10.
9. Franz, R., Kelly, S. L., Lamb, D. C., Kelly, D. E., Ruhnke, M. & Morschhäuser, J. (1998). Multiple molecular mechanisms contribute to a stepwise development of fluconazole resistance in clinical Candida albicans strains. Antimicrob Agents Chemother 42, 3065-3072.
10. Franz, R., Ruhnke, M. & Morschhäuser, J. (1999). Molecular aspects of fluconazole resistance development in Candida albicans. Mycoses 42, 453-458.
11. Gavin, A.-C., Bösche, M., Krause, R., Grandi, P., Marzioch, M., Bauer, A., Schultz, J., Rick, J. M., Michon, A.M. & other authors (2002). Functional organization of the yeast proteome by systematic analysis of protein complexes. Nature 415, 141-147.
12. Holmes, A. R., Lin, Y.-H., Niimi, K., Lamping, E., Keniya, M., Niimi, M., Tanabe, K., Monk, B. C. & Cannon, R. D. (2008). ABC transporter Cdr1p contributes more than Cdr2p does to fluconazole efflux in fluconazole-resistant Candida albicans clinical isolates. Antimicrob Agents Chemother 52, 3851-3862.
13. Jayatilake, J. A., Samaranayake, L. P., Lu, Q. & Jin, L. J. (2007). IL-1a, IL-1ra and IL-8 are differentially induced by Candida in experimental oral candidiasis. Oral Dis 13, 426-433.
14. Jin, Y., Samaranayake, L. P., Samaranayake, Y. & Yip, H. K. (2004). Biofilm formation of Candida albicans is variably affected by saliva and dietary sugars. Arch Oral Biol 49, 789-798.
15. Kusch, H., Biswas, K., Schwanfelder, S., Engelmann, S., Rogers, P. D., Hecker, M. & Morschhäuser, J. (2004). A proteomic approach to understanding the development of multidrug-resistant Candida albicans strains. Mol Genet Genomics 271, 554-565.
16. Lopez-Ribot, J. L., McAtee, R. K., Lee, L. N., Kirkpatrick, W. R., White, T. C., Sanglard, D. & Patterson, T. F. (1998). Distinct patterns of gene expression associated with development of fluconazole resistance in serial Candida albicans isolates from human immunodeficiency virusinfected patients with oropharyngeal candidiasis. Antimicrob Agents Chemother 42, 2932-2937.
17. Lu, Q., Jayatilake, J. A., Samaranayake, L. P. & Jin, L. (2006). Hyphal invasion of Candida albicans inhibits the expression of human bdefensins in experimental oral candidiasis. J Invest Dermatol 126, 2049-2056.
18. Lupetti, A., Danesi, R., Campa, M., Del Tacca, M. & Kelly, S. (2002). Molecular basis of resistance to azole antifungals. Trends Mol Med 8, 76-81.
19. Mateus, C., Crow, S. A., Jr & Ahearn, D. G. (2004). Adherence of Candida albicans to silicone induces immediate enhanced tolerance to fluconazole. Antimicrob Agents Chemother 48, 3358-3366.
20. Morschhäuser, J. (2002). The genetic basis of fluconazole resistance development in Candida albicans. Biochim Biophys Acta 1587, 240-248.
21. Mukherjee, P. K., Chandra, J., Kuhn, D. M. & Ghannoum, M. A. (2003). Mechanism of fluconazole resistance in Candida albicans biofilms: phase-specific role of efflux pumps and membrane sterols. Infect Immun 71, 4333-4340.
22. Nakamura, K., Niimi, M., Niimi, K., Holmes, A. R., Yates, J. E., Decottignies, A., Monk, B. C., Goffeau, A. & Cannon, R. D. (2001). Functional expression of Candida albicans drug efflux pump Cdr1p in a Saccharomyces cerevisiae strain deficient in membrane transporters. Antimicrob Agents Chemother 45, 3366-3374.
23. Navarro-García, F., Sánchez, M., Nombela, C. & Pla, J. (2001). Virulence genes in the pathogenic yeast Candida albicans. FEMS Microbiol Rev 25, 245-268.
24. Nett, J. E., Crawford, K., Marchillo, K. & Andes, D. R. (2010). Role of Fks1p and matrix glucan in Candida albicans biofilm resistance to an echinocandin, pyrimidine, and polyene. Antimicrob Agents Chemother 54, 3505-3508.
25. Perea, S., López-Ribot, J. L., Kirkpatrick, W. R., McAtee, R. K., Santillán, R. A., Martínez, M., Calabrese, D., Sanglard, D. & Patterson, T. F. (2001). Prevalence of molecular mechanisms of resistance to azole antifungal agents in Candida albicans strains displaying high-level fluconazole resistance isolated from human immunodeficiency virusinfected patients. Antimicrob Agents Chemother 45, 2676-2684.
26. Pfaffl, M. W. (2001). A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res 29, e45.
27. Pfaller, M. A. & Diekema, D. J. (2007). Epidemiology of invasive candidiasis: a persistent public health problem. Clin Microbiol Rev 20, 133-163.
28. Prasad, R. & Kapoor, K. (2004). Multidrug resistance in yeast Candida. Int Rev Cytol 242, 215-248.
29. Ramage, G., Bachmann, S., Patterson, T. F., Wickes, B. L. & López-Ribot, J. L. (2002). Investigation of multidrug efflux pumps in relation to fluconazole resistance in Candida albicans biofilms. J Antimicrob Chemother 49, 973-980.
30. Rognon, B., Kozovska, Z., Coste, A. T., Pardini, G. & Sanglard, D. (2006). Identification of promoter elements responsible for the regulation of MDR1 from Candida albicans, a major facilitator transporter involved in azole resistance. Microbiology 152, 3701-3722.
31. Ruhnke, M., Hartwig, K. & Kofla, G. (2008). New options for treatment of candidaemia in critically ill patients. Clin Microbiol Infect 14 (Suppl. 4), 46-54.
32. Samaranayake, L. P. & MacFarlane, T. W. (1990). Oral Candidosis. London: Wright.
33. Samaranayake, Y. H., Dassanayake, R. S., Jayatilake, J. A., Cheung, B. P., Yau, J. Y., Yeung, K. W. & Samaranayake, L. P. (2005). Phospholipase B enzyme expression is not associated with other virulence attributes in Candida albicans isolates from patients with human immunodeficiency virus infection. J Med Microbiol 54, 583-593.
34. Sanglard, D., Kuchler, K., Ischer, F., Pagani, J. L., Monod, M. & Bille, J. (1995). Mechanisms of resistance to azole antifungal agents in Candida albicans isolates from AIDS patients involve specific multidrug transporters. Antimicrob Agents Chemother 39, 2378-2386.
35. Seneviratne, C. J., Jin, L. & Samaranayake, L. P. (2008a). Biofilm lifestyle of Candida: a mini review. Oral Dis 14, 582-590.
36. Seneviratne, C. J., Jin, L. J., Samaranayake, Y. H. & Samaranayake, L. P. (2008b). Cell density and cell aging as factors modulating antifungal resistance of Candida albicans biofilms. Antimicrob Agents Chemother 52, 3259-3266.
37. Seneviratne, C. J., Wang, Y., Jin, L., Abiko, Y. & Samaranayake, L. P. (2008c). Candida albicans biofilm formation is associated with increased anti-oxidative capacities. Proteomics 8, 2936-2947.
38. Tumbarello, M., Posteraro, B., Trecarichi, E. M., Fiori, B., Rossi, M., Porta, R., de Gaetano Donati, K., La Sorda, M., Spanu, T. & other authors (2007). Biofilm production by Candida species and inadequate antifungal therapy as predictors of mortality for patients with candidemia. J Clin Microbiol 45, 1843-1850.
39. Vanden Bossche, H., Marichal, P. & Odds, F. C. (1994). Molecular mechanisms of drug resistance in fungi. Trends Microbiol 2, 393-400.
40. Walker, L. A., Gow, N. A. & Munro, C. A. (2010). Fungal echinocandin resistance. Fungal Genet Biol 47, 117-126.
41. White, T. C. (1997). Increased mRNA levels of ERG16, CDR, and MDR1 correlate with increases in azole resistance in Candida albicans isolates from a patient infected with human immunodeficiency virus. Antimicrob Agents Chemother 41, 1482-1487.
42. Wisplinghoff, H., Bischoff, T., Tallent, S. M., Seifert, H., Wenzel, R. P. & Edmond, M. B. (2004). Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. Clin Infect Dis 39, 309-317.